Login| Sign Up| Help| Contact|

Patent Searching and Data


Matches 551 - 600 out of 118,956

Document Document Title
WO/2016/090296A1
The present disclosure relates to certain amine derivatives of fused bicyclic heterocycles that inhibit the amine reuptake function of the biogenic amine transporters, dopamine transporter (DAT), serotonin transporter (SERT) and norepine...  
WO/2016/086261A1
The present invention relates to compounds of the formula I or II: (I) (II) processes for their preparation and their use as pharmaceutical agents or compositions in the treatment, of neurological disorders.  
WO/2016/088838A1
The present invention provides a compound having a novel P2X3 and/or P2X2/3 receptor antagonizing effect. A compound represented by formula (I): (in the formula, R1a is an optionally substituted alkyl or the like, R1b is a hydrogen atom ...  
WO/2016/089893A1
The present invention relates to pharmaceutical compositions of an non-steroidal anti- inflammatory drug (NSAIDs) such as, aspirin, diclofenac, ibuprofen, ketoprofen, or naproxen, or any pharmaceutically acceptable salts, solvates, or pr...  
WO/2016/090251A1
The present disclosure provides a method of treating seizure in a subject having aberrant alkaline phosphatase activities, comprising administering a therapeutically effective amount of at least one recombinant alkaline phosphatase to th...  
WO/2016/088797A1
Provided are: a nucleic acid that reduces toxicity caused by abnormal accumulation of an RNA-binding protein in cells and is usable for preventing or treating a neurodegenerative disease; and a prophylactic or therapeutic agent for a neu...  
WO/2016/089187A1
The present invention relates to: a cyclic peptide (cyclo [Cys-Gln-Arg-Pro-Pro-Arg-Cys] peptide) composed of the amino acid sequence of SEQ ID NO: 2; and a composition for apoptotic cell detection, drug delivery and imaging, containing t...  
WO/2016/089766A1
The disclosure provides a novel polymorph of Compound (I):, 2-((l-(2-(4-Fluorophenyl)-2-oxoethyl)piperidin-4- yl)methyl)isoindolin-l-one monohydrochloride dihydrate, i.e., Form (A) of Compound (Ι)·ΗΟ·2Η2O. Pharmaceutical compositio...  
WO/2016/088816A1
Provided are: a compact-sized granulate of zinc acetate hydrate, in which the loss of crystallization water is suppressed during a manufacturing process by controlling the material temperature of the granulate to lower than 40°C during ...  
WO/2016/088132A9
The invention relates to the compounds of formula I and formula II or its pharmaceutical acceptable salts, as well as polymorphs, solvates, enantiomers, stereoisomers and hydrates thereof. The pharmaceutical compositions comprising an ef...  
WO/2016/087489A1
The present invention relates to novel, selective, radiolabelled mGluR2 ligands which are useful for imaging and quantifying the metabotropic glutamate receptor mGluR2 in tissues, using positron-emission tomography (PET). The invention i...  
WO/2016/086357A1
Provided are methyl oxazole piperidine compounds, which are antagonists of orexin receptors, and compositions thereof. Provided are also methods for treatment or prevention of neurological and psychiatric disorders and diseases in which ...  
WO/2016/089304A1
The present invention provides a method of treating one or more sodium channel related diseases or disorders in an individual, including related symptoms. The method comprises administering to the individual a tetrahydropyridine derivati...  
WO/2016/090316A1
Disclosed is a composition suitable for oral administration and capable of treating individuals suffering from unipolar disorder, bipolar disorder and/or bipolar disorder with an unhealthy body weight. The composition comprises a combina...  
WO/2016/089997A1
The present invention provides methods of preventing and/or reducing risk of neurodegeneration of association cortex, and/or inhibiting or reversing formation of phosphorylated tau or COXIV in the prefrontal cortex of a mammal in need th...  
WO/2016/090317A1
Herein, compounds of formula (I), compositions and methods for modulating inclusion formation and stress granules in cells related to the onset of neurodegenerative diseases, musculoskeletal diseases, cancer, ophthalmological diseases, a...  
WO/2016/090230A1
The invention relates to HDAC inhibitors for the treatment of peripheral neuropathy in a subject in need thereof. Also provided herein are methods for treating peripheral neuropathy in a subject in need thereof comprising administering t...  
WO/2016/087487A1
The present invention relates to novel 6,7-dihydropyrazolo[1,5-α]pyrazin-4(5H)-one derivatives as negative allosteric modulators (NAMs) of the metabotropic glutamate receptor subtype 2 ("mGluR2"). The invention is also directed to pharm...  
WO/2016/088834A1
A compound shown by general formula (I) (in the formula, all of the symbols are as defined in the specification) has selective S1P5 receptor agonist activity due to having a linker from a phenyl group to a cyclic substituent in a dihydro...  
WO/2016/086358A1
Provided are hydroxymethyl piperidine compounds, which are antagonists of orexin receptors, and compositions thereof. Provided are also methods for treatment or prevention of neurological and psychiatric disorders and diseases in which o...  
WO/2016/087429A1
The present invention relates to specific dosages of an A2A antagonist for use as a medicament and in particular useful for the treatment of Parkinson Disease and Attention Deficit/Hyperactivity Disorder.  
WO/2016/088813A1
Provided are: a compound having an antagonistic activity on an orexin receptor, a pharmaceutically acceptable salt of the compound, or a solvate of the compound or the pharmaceutically acceptable salt; a pharmaceutical composition charac...  
WO/2016/090154A1
Provided herein are methods of treating multiple sclerosis with dimethyl fumarate using an up-titration regimen. The methods provided herein are to reduce dimethyl fumarate-related gastro-intestinal adverse events in multiple sclerosis p...  
WO/2016/089251A1
The invention relates to the field of medicine, and more particularly to pharmacology, and even more particularly to pharmaceutical compositions for treating various conditions associated with a lack of energy potential resulting from...  
WO/2016/086842A1
Provided is a dihydro-β-agarofuran sesquiterpenoid, preparation method and use thereof, having a resistive function against ectoenzyme amyloid protein (Aβ)-induced neurocyte injuries and scopolamine-induced memory and behavior injuries...  
WO/2016/082789A1
Described herein are neuroactive steroids of the Formula (II) : or a pharmaceutically acceptable salt thereof; wherein A, R1, R2a, R2b, R3a, R3b, R4a, R4b, R5, R6 and ----- are as defined herein. Such compounds are envisioned, in certain...  
WO/2016/083458A1
The present invention relates to iPSC produced from fibroblast obtained from a subject affected by a neurodevelopmental disorder entailing intellectual disability (ID) and/or a disorder belonging to the Autism Spectrum Disorder (ASD) and...  
WO/2016/084921A1
[Problem] To develop a particulate composition whereby terahertz waves can be utilized on an ordinary basis. [Solution] A particulate composition characterized by having porous particulate silicon oxide as a main component thereof and fu...  
WO/2016/086157A1
Infant formulas that include at least one human milk oligosaccharide selected from 2'-fucosyllactose (2'-FL) and lacto-N-neotetraose (LNnT), polyunsaturated fatty acids (PUFAs) docosahexaenoic acid (DHA) and arachidonic acid (AA), where ...  
WO/2016/082798A1
Disclosed are an α-cyan-4-hydroxycinnamic acid derivative having aldose reductase (AR) inhibitory activity and a preparation method and use thereof, the compound having a structure as represented by formula I, and the preparation method...  
WO/2016/083875A1
Opicapone, levodopa and an AADC inhibitor are described for use in slowing the progression of Parkinson's Disease.  
WO/2016/086151A1
Infant formulas that include a combination of RRR-alpha-tocopherol, 2'-fucosyllactose, and at least one probiotic from the Lactobacillus or the Bifidobacterium genera are disclosed. Also provided are methods of use of the infant formulas...  
WO/2016/085998A1
The present disclosure relates generally to methods for treating neurodegenerative diseases, including their progressive forms. In particular, the present disclosure pertains to methods of treating or preventing neurodegenerative disease...  
WO/2016/086136A1
The invention relates to fatty acid cysteamine conjugates of a CFTR modulator, compositions comprising a fatty acid cysteamine conjugate of a CFTR modulator, and methods for using such conjugates and compositions to treat disease, such a...  
WO/2016/083490A1
This invention provides novel compounds of formulae (I) or (II) or a stereoisomer, enantiomer, racemic, or tautomer thereof, (I) (II) wherein the substituents are as defined in the specification. The present invention also relates to the...  
WO/2016/086194A1
Methods and compositions for potentiating the effect of an opioid analgesic in a patient undergoing or planning to undergo opioid analgesic therapy using a potentiating amount of iboga alkaloid or pharmaceutically acceptable salt and/or ...  
WO/2016/084866A1
Provided are: compounds having orexin receptor antagonistic effects; a pharmaceutical composition characterized by comprising the compounds as an active ingredient; and medical applications thereof, particularly prophylactic and/or thera...  
WO/2016/084790A1
The present invention provides a compound represented by general formula (I) which has excellent retinoic acid receptor-related orphan receptor γt inhibitory activity and IL-17 production inhibitory activity, or a pharmaceutically accep...  
WO/2016/082241A1
Disclosed is a DHA nanoemulsion. The DHA nanoemulsion consists of the following components in parts by weight: 0.5 to 2 parts of DHA, 1 to 4 parts of VE, 4 to 8 parts of surfactant I, 10 to 20 parts of surfactant II, 1 to 4 parts of VC, ...  
WO/2016/086113A1
The presently described technology provides compositions comprising aryl carboxylic acids and, for example NSAIDs, chemically conjugated to oxycodone (4,5-α-epoxy-14-hydroxy-17-methylmorphinan-6-one) to form novel prodrugs/compositions ...  
WO/2016/083863A1
Medicaments for use in slowing the progression of Parkinson's Disease.  
WO/2016/084290A1
[Problem] To provide a novel food or beverage capable of lowering blood alcohol level. [Solution] A food or beverage containing a water-insoluble component that is derived from a fruit. The food or beverage may be in the form of, for exa...  
WO/2016/084816A1
Provided is a bicyclic compound having an inhibitory effect on acetyl-CoA carboxylase. A compound represented by the formula: (in the formula, each of the symbols is as defined in the specification) or a salt thereof has an inhibitory ef...  
WO/2016/082780A1
The present invention relates to α-asary-laldehyde ester, a preparation method therefor, and an application thereof. The chemical structure of the related α-asary-laldehyde ester is represented by formula I. A related application is an...  
WO/2016/084870A1
Provided is an acylaminophenyl-group-containing compound having a neuroprotective effect. Also provided is a neuroprotective agent including an acylaminophenyl-group-containing compound. A novel acylaminophenyl-group-containing compound,...  
WO/2016/084412A1
It is found that the activation of a B cell can be inhibited by TGF-beta3 produced by LAG3+ Treg. A B cell activation inhibitor comprising TGF-beta3 or a molecule having the function of TGF-beta3 and a therapeutic agent for autoimmune di...  
WO/2016/079595A3
The preparation of the present invention was found to be effective for the majority of patients diagnosed with autism. In patients characterized by delayed language development and non- expressive/non-emotional communication patterns, th...  
WO/2016/078032A1
Disclosed is a mixed formulation of multiple natural plant extracts having a pain-relieving function and a preparation method thereof. The formulation comprises: 13-17% of an Amaranthaceae extract, such as amaranth; 18-22% of a Labiatae ...  
WO/2016/080853A1
Compounds of formula (II) are provided for stabilizing protein transthyretin (TTR) and inhibiting amyloid fibril formation, for example, transthyretin-mediated amyloid fibril formation, and for treating, preventing, or ameliorating one o...  
WO/2016/081640A1
The present invention relates to bispecific antibodies that bind to transferrin receptor and BACE1 and methods of using the same.  

Matches 551 - 600 out of 118,956